psilocybin
/ Dominari Holdings
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 16, 2021
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
(PRNewswire)
- “AIkido Pharma…announced the execution of a Letter of Intent with Silo Pharma…to grant to AIkido a worldwide, exclusive sublicense for use of peptide therapy, combined with psilocybin, in the therapeutic treatment of neuroinflammatory disease in cancer patients…AIkido Pharma and Silo and these additional assets expand the Company's asset base in the area of psilocybin to treat cancer.”
Licensing / partnership • Oncology
January 06, 2021
AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications
(PRNewswire)
- "AIkido Pharma Inc...announced that the Company executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications....Research has shown psilocybin to have potential to treat a range of psychiatric and behavioral disorders, notably, cancer-related depression and anxiety."
Patent • Oncology
1 to 2
Of
2
Go to page
1